{
    "name": "viltolarsen",
    "comment": "Rx",
    "other_names": [
        "Viltepso"
    ],
    "classes": [
        "Neurologics",
        "Antisense Oligonucleotides"
    ],
    "source": "https://reference.medscape.com/drug/viltepso-viltolarsen-4000040",
    "pregnancy": {
        "common": [
            "There are no human or animal data available"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "There are no human or animal data to assess effect on milk production"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [],
            "specific": [
                {
                    "type": "Kidney toxicity",
                    "description": [
                        "Kidney toxicity observed in animals",
                        "Clinical experience with viltolarsen is limited, and kidney toxicity, including potentially fatal glomerulonephritis, has been observed after administration of some antisense oligonucleotides",
                        "Monitor kidney function during treatment",
                        "Only urine expected to be free of excreted drug should be used for monitoring of urine protein; urine obtained on the day of infusion, prior to infusion, or urine obtained at least 48 hr after most recent infusion, may be used; alternatively, use a laboratory test that does not use the reagent pyrogallol red, as this reagent has potential to cross react with any drug that is excreted in urine and thus lead to a false positive result for urine protein",
                        "Serum creatinine may not reliably measure kidney function in patients with DMD owing to reduced skeletal muscle mass",
                        "Measure serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio before initiating",
                        "Consider measuring GFR using an exogenous filtration marker before initiating",
                        "During treatment, monitor urine dipstick every month and serum cystatin C and urine protein-to-creatinine ratio q3Months",
                        "If persistent increased serum cystatin C or proteinuria detected, refer to a pediatric nephrologist for further evaluation"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Upper respiratory tract infection",
            "percent": "63"
        },
        {
            "name": "Injection site reaction",
            "percent": "25"
        },
        {
            "name": "Cough",
            "percent": "19"
        },
        {
            "name": "Pyrexia",
            "percent": "19"
        },
        {
            "name": "Contusion",
            "percent": "13"
        },
        {
            "name": "Arthralgia",
            "percent": "13"
        },
        {
            "name": "Diarrhea",
            "percent": "13"
        },
        {
            "name": "Vomiting",
            "percent": "13"
        },
        {
            "name": "Abdominal pain",
            "percent": "13"
        },
        {
            "name": "Ejection fraction decreased",
            "percent": "13"
        },
        {
            "name": "Urticaria",
            "percent": "13"
        }
    ]
}